Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Olinciguat (Primary)
- Indications Achalasia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ironwood Pharmaceuticals
- 06 May 2021 Status changed to discontinued.
- 05 Dec 2018 Status changed from active, no longer recruiting to completed.
- 15 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.